乳腺癌患者新辅助化学治疗后ERCC1基因表达情况研究

Expression of ERCC1 Gene in Breast Cancer after Neoadjuvant Chemotherapy

目的研究乳腺癌新辅助化学治疗(简称化疗)对核苷酸切除修复基因ERCC1表达的影响及临床意义。方法逆转录聚合酶链式反应(RT-PCR)检测正常健康志愿者活检组织(18例),常规手术切除的乳腺癌标本(28例)和术前曾接受新辅助化疗的乳腺癌标本(18例)中ERCC1基因的表达,分析其表达与乳腺癌临床病理特征的相关性以及乳腺癌新辅助化疗对其的影响。结果无化疗组患者的ERCC1基因表达水平显著低于正常组(P<0.05)。无化疗组乳腺癌中ERCC1基因表达水平与患者的年龄、肿瘤大小、淋巴结转移、病理分型、组织学分级、雌激素受体(ER)、孕激素受体(PR)和人表皮因子受体-2(HER-2)均无明显相关性(P>0.05)。新辅助化疗组ERCC1基因的表达水平明显高于无化疗组(P<0.05)。结论与正常人相比,乳腺癌患者ERCC1基因表达水平显著下降(P<0.05),而ERCC1基因的表达水平与乳腺癌的临床病理特征无相关性,患者经过新辅助化疗后ERCC1基因的表达水平可出现上调,对乳腺癌患者实施化疗治疗具有参考意义。

Objective To study the expression of ERCC1 gene in breast cancer after neoadjuvant chemotherapy. Methods The expres- sion of ERCC1 gene was detected by RT-PCR in 28 breast cancer patients without neoadjuvant chemotherapy and in 18 breast cancer patients treated with neoadjuvant chemotherapy. The expression and clinicopathologieal features of breast cancer as well as the relevance of the impact of neoadjuvant chemotherapy on it were analyzed. Results No chemotherapy patients ERCC1 expression level was signifi- cantly lower than the normal group, the difference was statistically significant（ P 〈 0.05）. The differences of ERCC1 gene expression levels of the non chemotherapy group between different ages, tumor sizes, histological types, histological grades, axillary lymph nodes, PR, ER, HER-2 were not significant（P 〉 0.05）. Neoadjuvant chemotherapy group ERCC1 gene expression levels were significantly higher than those without chemotherapy group, the difference was statistically significant（ P 〈 0.05）. Conclusion Compared with the normal, ERCCI gene expression levels were significantly decreased in patients with breast eancer（P 〈 0.05） and ERCC1 gene expression and Clinical pathological characteristics of breast cancer not associated, after neo- adjuvant chemotherapy in patients with raised the ERCC1 gene expression can occur, chemotherapy in the treatment of breast cancer patients have some reference value.